|Articles|February 1, 1998

Clinical and Economic Considerations in the Prevention of Osteoporosis Among Postmenopausal Women
Volume 4
Issue 2 Suppl

Current Approaches to Osteoporosis Prevention

Author(s)Robert Lindsay, MD, PhD, Nelson B. Watts, MD, Donna Shoupe, MD

Download PDF: Current Approaches to Osteoporosis Prevention

Articles in this issue

over 28 years ago

Article

Participating Faculty

over 28 years ago

Article

Introduction: Approaches to Prevention of Postmenopausal Osteoporosis -- The Impact of Emerging Therapies

over 28 years ago

Article

Patient-Provider Decisions About Long-Term Therapy

over 28 years ago

Article

Potential Impact of Emerging Therapies on Osteoporosis Prevention

over 28 years ago

Article

An Emerging Approach to Osteoporosis Prevention

over 28 years ago

Article

The Management of the Patient with Osteoporosis: A Modern Epidemic

over 28 years ago

Article

CME Quiz

over 28 years ago

Article

Selected Abstracts

over 28 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Current Approaches to Osteoporosis Prevention

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Zanubrutinib Tops Rivals in Real-World CLL Survival Study

Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Current Approaches to Osteoporosis Prevention

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Zanubrutinib Tops Rivals in Real-World CLL Survival Study

Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups